CN Patent

CN104768555A — 用于治疗癌症的联合治疗

Assigned to Epizyme Inc · Expires 2015-07-08 · 11y expired

What this patent protects

本发明涉及包含人组蛋白甲基转移酶EZH2的抑制剂以及一种或多种其它治疗试剂(尤其是抗癌试剂诸如波尼松)的组合物，以及用于治疗癌症的向有需求的主体施用的联合治疗的方法。

USPTO Abstract

本发明涉及包含人组蛋白甲基转移酶EZH2的抑制剂以及一种或多种其它治疗试剂(尤其是抗癌试剂诸如波尼松)的组合物，以及用于治疗癌症的向有需求的主体施用的联合治疗的方法。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN104768555A
Jurisdiction: CN
Classification: —
Expires: 2015-07-08
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.